Thomas Charles Reilly - Net Worth and Insider Trading
Thomas Charles Reilly Net Worth
The estimated net worth of Thomas Charles Reilly is at least $16,429 dollars as of 2024-12-26. Thomas Charles Reilly is the CFO of Cara Therapeutics Inc and owns about 37,811 shares of Cara Therapeutics Inc (CARA) stock worth over $16,429. Details can be seen in Thomas Charles Reilly's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas Charles Reilly has not made any transactions after 2022-03-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Thomas Charles Reilly
Thomas Charles Reilly Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Charles Reilly owns 2 companies in total, including Cara Therapeutics Inc (CARA) , and Amarin Corp PLC (AMRN) .
Click here to see the complete history of Thomas Charles Reilly’s form 4 insider trades.
Insider Ownership Summary of Thomas Charles Reilly
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CARA | Cara Therapeutics Inc | 2022-03-03 | Chief Financial Officer |
| AMRN | Amarin Corp PLC | 2023-02-21 | SVP and CFO |
Thomas Charles Reilly Latest Holdings Summary
Thomas Charles Reilly currently owns a total of 1 stock. Thomas Charles Reilly owns 37,811 shares of Cara Therapeutics Inc (CARA) as of March 3, 2022, with a value of $16,429.
Latest Holdings of Thomas Charles Reilly
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CARA | Cara Therapeutics Inc | 2022-03-03 | 37,811 | 0.43 | 16,429 |
Holding Weightings of Thomas Charles Reilly
Thomas Charles Reilly Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Charles Reilly has made a total of 2 transactions in Cara Therapeutics Inc (CARA) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Cara Therapeutics Inc is the sale of 2,044 shares on March 3, 2022, which brought Thomas Charles Reilly around $23,261.
Insider Trading History of Thomas Charles Reilly
- 1
Thomas Charles Reilly Trading Performance
Thomas Charles Reilly Ownership Network
Thomas Charles Reilly Owned Company Details
What does Cara Therapeutics Inc do?
Who are the key executives at Cara Therapeutics Inc?
Thomas Charles Reilly is the Chief Financial Officer of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .
Cara Therapeutics Inc (CARA) Insider Trades Summary
Over the past 18 months, Thomas Charles Reilly made no insider transaction in Cara Therapeutics Inc (CARA). Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 60,412 shares made by Christopher Posner , a net sale of 2,753 shares made by Scott Terrillion , and a net sale of 2,753 shares made by Joana Goncalves .
In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 65,918 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 65,918 shares.
Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cara Therapeutics Inc Insider Transactions
Thomas Charles Reilly Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Charles Reilly. You might contact Thomas Charles Reilly via mailing address: C/o Cara Therapeutics, Inc., 4 Stamford Plaza, 107 Elm Street, Stamford Ct 06902.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
